For Moderna, speedy vaccine development means skipping a big step
Moderna Therapeutics got a potential coronavirus vaccine from inception to trial-readiness in 42 days, setting an industry record. But moving that fast meant skipping the part where you test whether a would-be vaccine works in an animal exposed to the virus, adding uncertainty to a fluid situation.
As STAT’s Eric Boodman reports, this isn’t how vaccine development usually happens. Demonstrating efficacy in lab animals is normally a key step that proceeds human trials. But the coronavirus outbreak, which has resulted in more than 125,000 cases around the world, is not a normal setting.
The rapid pace of Moderna’s vaccine, for which a clinical trial is already recruiting, compounds an already risky situation. Moderna’s technique of using messenger RNA to create medicines has never proved itself in a large trial, much less resulted in an approved product.
Read more.
As STAT’s Eric Boodman reports, this isn’t how vaccine development usually happens. Demonstrating efficacy in lab animals is normally a key step that proceeds human trials. But the coronavirus outbreak, which has resulted in more than 125,000 cases around the world, is not a normal setting.
The rapid pace of Moderna’s vaccine, for which a clinical trial is already recruiting, compounds an already risky situation. Moderna’s technique of using messenger RNA to create medicines has never proved itself in a large trial, much less resulted in an approved product.
Read more.
.png)
No hay comentarios:
Publicar un comentario